CRL vs. WAT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CRL and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CRL | WAT |
|---|---|---|
| Company Name | Charles River Laboratories International, Inc. | Waters Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 7.85 billion USD | 17.66 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 23, 2000 | November 17, 1995 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CRL and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CRL | WAT |
|---|---|---|
| 5-Day Price Return | 2.43% | 1.09% |
| 13-Week Price Return | 12.87% | -17.24% |
| 26-Week Price Return | 4.18% | -21.73% |
| 52-Week Price Return | -21.78% | -12.79% |
| Month-to-Date Return | -5.93% | 2.76% |
| Year-to-Date Return | -13.55% | -20.01% |
| 10-Day Avg. Volume | 0.99M | 0.62M |
| 3-Month Avg. Volume | 1.26M | 0.68M |
| 3-Month Volatility | 40.52% | 38.48% |
| Beta | 1.53 | 1.06 |
Profitability
Return on Equity (TTM)
CRL
-2.01%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
CRL has a negative Return on Equity of -2.01%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
WAT
35.02%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
WAT’s Return on Equity of 35.02% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
CRL
-1.72%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
CRL has a negative Net Profit Margin of -1.72%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
WAT
21.71%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
A Net Profit Margin of 21.71% places WAT in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
CRL
3.09%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
CRL’s Operating Profit Margin of 3.09% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
WAT
27.69%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 27.69% places WAT in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | CRL | WAT |
|---|---|---|
| Return on Equity (TTM) | -2.01% | 35.02% |
| Return on Assets (TTM) | -0.90% | 14.40% |
| Net Profit Margin (TTM) | -1.72% | 21.71% |
| Operating Profit Margin (TTM) | 3.09% | 27.69% |
| Gross Profit Margin (TTM) | 35.03% | 59.02% |
Financial Strength
Current Ratio (MRQ)
CRL
1.36
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
CRL’s Current Ratio of 1.36 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
WAT
1.75
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
WAT’s Current Ratio of 1.75 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CRL
0.70
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
CRL’s Debt-to-Equity Ratio of 0.70 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
WAT
0.67
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
WAT’s Debt-to-Equity Ratio of 0.67 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
CRL
1.71
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s Interest Coverage Ratio of 1.71 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
WAT
11.29
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
WAT’s Interest Coverage Ratio of 11.29 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | CRL | WAT |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 1.75 |
| Quick Ratio (MRQ) | 0.96 | 1.22 |
| Debt-to-Equity Ratio (MRQ) | 0.70 | 0.67 |
| Interest Coverage Ratio (TTM) | 1.71 | 11.29 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
CRL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
WAT
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
CRL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
WAT
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CRL | WAT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CRL
--
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
P/E Ratio data for CRL is currently unavailable.
WAT
26.76
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, WAT’s P/E Ratio of 26.76 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
CRL
1.92
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s P/S Ratio of 1.92 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
WAT
5.81
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
WAT’s P/S Ratio of 5.81 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
CRL
2.22
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
CRL’s P/B Ratio of 2.22 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
WAT
9.62
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
At 9.62, WAT’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | CRL | WAT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 26.76 |
| Price-to-Sales Ratio (TTM) | 1.92 | 5.81 |
| Price-to-Book Ratio (MRQ) | 2.22 | 9.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 13.40 | 28.57 |